Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer’s Disease: A Review of Clinical Trials
Background. Acetylcholinesterase (AChE)/cholinesterase (ChE) inhibitors (Is) and memantine are licensed for symptomatic treatment of mild-moderate and moderate-severe forms of Alzheimer’s disease (AD), respectively. High doses of the AChE-I donepezil were licensed in the USA for moderate-severe AD,...
Saved in:
Main Authors: | Ivana Molino, Luisa Colucci, Angiola M. Fasanaro, Enea Traini, Francesco Amenta |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | The Scientific World Journal |
Online Access: | http://dx.doi.org/10.1155/2013/925702 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Normal Hearing Ability but Impaired Auditory Selective Attention Associated with Prediction of Response to Donepezil in Patients with Alzheimer’s Disease
by: Yoshitaka Ouchi, et al.
Published: (2015-01-01) -
RP-HPLC Method for the Estimation of Donepezil Hydrochloride Dosage Form
by: Tushar G. Barot, et al.
Published: (2009-01-01) -
Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial
by: Remo Panaccione, et al.
Published: (2011-01-01) -
Memantine-responsive catatonia secondary to tuberculosis, neurocysticercosis, and pneumococcal pneumonia: A case series
by: Debanjan Bhattacharjee, et al.
Published: (2023-11-01) -
Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials
by: Jing Yang, et al.
Published: (2020-01-01)